PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities

PIK3CA mutation as an acquired resistance driver to EGFR-TKIs in non-small cell lung cancer: Clinical challenges and opportunities

Epithelial growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) have significantly enhanced the treatment outcomes in non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. However, the occurrence of acquired resistance to EGFR-TKIs is an unavoidable outcome observed in the...

Full description

Bibliographic Details
Main Authors: Xiaohong Liu, Wuxuan Mei, Pengfei Zhang, Changchun Zeng
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:Pharmacological Research
Subjects:
Non-small cell lung cancer
EGFR
Resistance
PIK3CA
Combined therapy
Online Access:http://www.sciencedirect.com/science/article/pii/S1043661824000677

Internet

http://www.sciencedirect.com/science/article/pii/S1043661824000677

Similar Items